These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
381 related articles for article (PubMed ID: 25883128)
41. Contribution of 5th minute and 2nd hour images to standard imaging in ( Can C; Komek H Ann Nucl Med; 2020 Mar; 34(3):163-173. PubMed ID: 31808135 [TBL] [Abstract][Full Text] [Related]
42. Combined model-based and patient-specific dosimetry for Plyku D; Mena E; Rowe SP; Lodge MA; Szabo Z; Cho SY; Pomper MG; Sgouros G; Hobbs RF Eur J Nucl Med Mol Imaging; 2018 Jun; 45(6):989-998. PubMed ID: 29460025 [TBL] [Abstract][Full Text] [Related]
43. 2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer. Chen Y; Pullambhatla M; Foss CA; Byun Y; Nimmagadda S; Senthamizhchelvan S; Sgouros G; Mease RC; Pomper MG Clin Cancer Res; 2011 Dec; 17(24):7645-53. PubMed ID: 22042970 [TBL] [Abstract][Full Text] [Related]
44. Antihormone treatment differentially regulates PSA secretion, PSMA expression and Mathy CS; Mayr T; Kürpig S; Meisenheimer M; Dolscheid-Pommerich RC; Stoffel-Wagner B; Kristiansen G; Essler M; Muders MH; Bundschuh RA J Cancer Res Clin Oncol; 2021 Jun; 147(6):1733-1743. PubMed ID: 33760944 [TBL] [Abstract][Full Text] [Related]
46. Initial Evaluation of [(18)F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer. Szabo Z; Mena E; Rowe SP; Plyku D; Nidal R; Eisenberger MA; Antonarakis ES; Fan H; Dannals RF; Chen Y; Mease RC; Vranesic M; Bhatnagar A; Sgouros G; Cho SY; Pomper MG Mol Imaging Biol; 2015 Aug; 17(4):565-74. PubMed ID: 25896814 [TBL] [Abstract][Full Text] [Related]
47. Biodistribution and internal radiation dosimetry of a companion diagnostic radiopharmaceutical, [ Kim SB; Song IH; Song YS; Lee BC; Gupta A; Lee JS; Park HS; Kim SE Sci Rep; 2021 Jul; 11(1):15263. PubMed ID: 34315965 [TBL] [Abstract][Full Text] [Related]
48. Preliminary Evaluation of Lee H; Scheuermann JS; Young AJ; Doot RK; Daube-Witherspoon ME; Schubert EK; Fillare MA; Alexoff D; Karp JS; Kung HF; Pryma DA Mol Imaging Biol; 2022 Oct; 24(5):710-720. PubMed ID: 35349040 [TBL] [Abstract][Full Text] [Related]
49. Biodistribution and radiation dosimetry of [ Hohberg M; Kobe C; Krapf P; Täger P; Hammes J; Dietlein F; Zlatopolskiy BD; Endepols H; Wild M; Neubauer S; Heidenreich A; Neumaier B; Drzezga A; Dietlein M EJNMMI Res; 2019 Jul; 9(1):66. PubMed ID: 31346821 [TBL] [Abstract][Full Text] [Related]
51. 68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies. Weineisen M; Schottelius M; Simecek J; Baum RP; Yildiz A; Beykan S; Kulkarni HR; Lassmann M; Klette I; Eiber M; Schwaiger M; Wester HJ J Nucl Med; 2015 Aug; 56(8):1169-76. PubMed ID: 26089548 [TBL] [Abstract][Full Text] [Related]
52. Dosimetry for (177)Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer. Delker A; Fendler WP; Kratochwil C; Brunegraf A; Gosewisch A; Gildehaus FJ; Tritschler S; Stief CG; Kopka K; Haberkorn U; Bartenstein P; Böning G Eur J Nucl Med Mol Imaging; 2016 Jan; 43(1):42-51. PubMed ID: 26318602 [TBL] [Abstract][Full Text] [Related]
53. van Boxtel W; Lütje S; van Engen-van Grunsven ICH; Verhaegh GW; Schalken JA; Jonker MA; Nagarajah J; Gotthardt M; van Herpen CML Theranostics; 2020; 10(5):2273-2283. PubMed ID: 32089741 [No Abstract] [Full Text] [Related]
54. Development and first-in-human study of PSMA-targeted PET tracers with improved pharmacokinetic properties. Hou H; Pan Y; Wang Y; Ma Y; Niu X; Sun S; Hou G; Tao W; Gao F Eur J Nucl Med Mol Imaging; 2024 Jul; 51(9):2819-2832. PubMed ID: 38683349 [TBL] [Abstract][Full Text] [Related]
55. The Impact of Monosodium Glutamate on Armstrong WR; Gafita A; Zhu S; Thin P; Nguyen K; Alano R; Lira S; Booker K; Gardner L; Grogan T; Elashoff D; Allen-Auerbach M; Dahlbom M; Czernin J; Calais J J Nucl Med; 2021 Sep; 62(9):1244-1251. PubMed ID: 33509974 [TBL] [Abstract][Full Text] [Related]
56. von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806 [TBL] [Abstract][Full Text] [Related]
57. Biokinetics and dosimetry of Hvittfeldt E; Bjöersdorff M; Brolin G; Minarik D; Svegborn SL; Oddstig J; Trägårdh E Clin Physiol Funct Imaging; 2022 Nov; 42(6):443-452. PubMed ID: 36039853 [TBL] [Abstract][Full Text] [Related]
58. Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer-Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis. Perera M; Papa N; Roberts M; Williams M; Udovicich C; Vela I; Christidis D; Bolton D; Hofman MS; Lawrentschuk N; Murphy DG Eur Urol; 2020 Apr; 77(4):403-417. PubMed ID: 30773328 [TBL] [Abstract][Full Text] [Related]
59. In Vitro and In Vivo Characterization of an Lütje S; Franssen GM; Herrmann K; Boerman OC; Rijpkema M; Gotthardt M; Heskamp S J Nucl Med; 2019 Jul; 60(7):1017-1022. PubMed ID: 30655329 [TBL] [Abstract][Full Text] [Related]
60. Preliminary results of biodistribution and dosimetric analysis of [ Khawar A; Eppard E; Roesch F; Ahmadzadehfar H; Kürpig S; Meisenheimer M; Gaertner FC; Essler M; Bundschuh RA Ann Nucl Med; 2019 Jun; 33(6):404-413. PubMed ID: 30877560 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]